Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Effect of Food on Selumetinib in Adolescents with Neurofibromatosis Type 1 Plexiform Neurofibromas

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition called Neurofibromatosis Type 1 (NF1), which is a genetic disorder that often leads to the development of tumors along nerves in the skin, brain, and other parts of the body. Specifically, the study is looking at a type of tumor known as plexiform neurofibromas (PN), which are complex nerve tumors that can cause various health issues. The treatment being tested in this study is a medication called Selumetinib, also known by its code name AZD6244. This medication is taken in the form of hard capsules and is being evaluated for its effects when taken with food.

The purpose of the study is to understand how a low-fat meal affects the way Selumetinib is processed in the body and its impact on the stomach and intestines. The study involves adolescent children who have NF1-related plexiform neurofibromas. Participants will take part in different treatment periods where they will receive multiple doses of Selumetinib. During these periods, the study will assess how the medication is absorbed and tolerated by the body, especially when taken with or without food.

Throughout the study, participants will be monitored for any side effects, and their overall health will be assessed through various tests, including blood tests and heart function tests. The study aims to gather information on the safety and tolerability of Selumetinib in young patients with NF1-related plexiform neurofibromas, providing valuable insights into how the medication can be used effectively in managing this condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants are required to provide signed consent from a parent or legal guardian, along with their own assent if applicable. This consent includes agreement to comply with study requirements and restrictions.

    Participants must be between 12 and 18 years old and diagnosed with Neurofibromatosis Type 1 (NF1) with inoperable plexiform neurofibromas (PN).

  2. Step 2

    Treatment period 1 (T1)

    Participants begin taking selumetinib capsules, which are available in 10 mg and 25 mg doses. The medication is taken orally.

    The effect of a low-fat meal on the medication's absorption and gastrointestinal tolerability is assessed during this period.

  3. Step 3

    Treatment period 2 (T2)

    Participants continue taking selumetinib capsules, but this time in a fasted state to compare the effects with those observed in T1.

    The focus is on understanding how fasting affects the medication's absorption and any gastrointestinal side effects.

  4. Step 4

    Treatment period 3 (T3)

    The decision to proceed to T3 depends on the results from T1 and T2.

    Participants may take selumetinib capsules again with a low-fat meal to further evaluate the medication's effects.

  5. Step 5

    Monitoring and assessments

    Throughout the study, participants undergo regular assessments to monitor safety and tolerability. This includes checking for any side effects, conducting laboratory tests, and performing physical examinations.

    Participants are required to maintain a diary to record any gastrointestinal symptoms, using a specific rating scale.

  6. Step 6

    Completion of the study

    The study is estimated to conclude by June 2028. Participants will have a final assessment to evaluate the overall effects of the treatment.

    The study aims to provide insights into how food affects the absorption and side effects of selumetinib in adolescents with NF1-related PN.

Who can join the trial?

10 criteria

  • Participants must be boys or girls aged 12 to less than 18 years old.
  • A signed consent form from a parent or legal guardian is required, along with the child's agreement to participate, if applicable. If the participant reaches the age of legal consent during the study, they will need to sign a new consent form.
  • Participants must have a diagnosis of Neurofibromatosis Type 1 (NF1) and have inoperable Plexiform Neurofibromas (PN). NF1 is a genetic condition that can cause tumors to grow on nerves. PN are a type of tumor that cannot be completely removed by surgery without causing significant harm.
  • Participants must need treatment for NF1 and inoperable PN due to symptoms or the risk of serious health problems, as determined by the study doctor. This includes issues like tumors that could affect breathing, cause nerve damage, or lead to significant disfigurement or pain.
  • Participants who have previously been treated with any MEK inhibitor (a type of medication), including selumetinib, may join the study.
  • Participants older than 16 must have a Karnofsky performance level of 70 or higher, and those 16 or younger must have a Lansky performance level of 70 or higher. These are scales used to measure a person's ability to perform daily activities. Participants who use a wheelchair due to paralysis from a PN are considered able to move around if they can do so in their wheelchair.
  • Participants must have a Body Surface Area (BSA) between 1.3 and 2.5 square meters. BSA is a measurement used to calculate medication doses based on a person's size.
  • Participants must be able to swallow whole capsules.
  • Participants must agree to participate in all three treatment periods of the study.
  • Female participants who can become pregnant must use a highly effective method of birth control if they are sexually active. They must have a negative pregnancy test before starting the study and before each treatment period. Male participants must use a condom with spermicide if they have a female partner who can become pregnant, and they must not donate sperm during the study.

Who cannot join the trial?

9 criteria

  • Patients who are not diagnosed with Neurofibromatosis Type 1 (NF1), a genetic disorder that causes tumors to grow on nerves.
  • Patients who do not have Plexiform Neurofibromas (PN), which are a type of tumor associated with NF1.
  • Patients who are outside the age range specified for the study.
  • Patients who are not able to take the study medication as required.
  • Patients who have other medical conditions that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial.
  • Patients who have allergies to the study medication or its ingredients.
  • Patients who are unable to follow the study procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Selumetinib is a medication being studied for its effects on children with a condition called Neurofibromatosis Type 1 (NF1), which can cause tumors known as plexiform neurofibromas. This trial is looking at how the body absorbs and tolerates the medication when taken with food. The goal is to understand if eating a low-fat meal changes how the medication works in the body after taking it multiple times.

What is already known about the treatment

Selumetinib – Selumetinib is administered orally in capsule form. It is currently being studied in clinical trials for its effects on gastrointestinal tolerability and pharmacokinetics when taken with food, specifically in adolescent children with Neurofibromatosis Type 1 (NF1) related plexiform neurofibromas. The main therapeutic indication for selumetinib is the treatment of these neurofibromas, which are a type of tumor associated with NF1. At the molecular level, selumetinib works by inhibiting a specific enzyme in the MAPK/ERK pathway, which is involved in cell growth and division. It is classified pharmacologically as a MEK inhibitor, targeting the MEK1 and MEK2 proteins to help reduce tumor growth.

Investigated diseases

Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN) – This is a genetic disorder characterized by the development of multiple benign tumors called plexiform neurofibromas. These tumors grow along nerves and can affect various parts of the body, including the skin, eyes, and bones. The growth of these tumors is typically slow, but they can become large and cause physical disfigurement or functional impairment. Plexiform neurofibromas are often present at birth or develop in early childhood. They can vary greatly in size and number among individuals with NF1. The condition is caused by mutations in the NF1 gene, which is responsible for producing a protein that helps regulate cell growth.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-517216-29-00Protocol codeD1346C00015Estimated enrolment20 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).